Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2025

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients

J Dermatol Treat 2025;36:2562299 Doi: 10.1080/09546634.2025.2562299

Qiao Z,

Chai B,

Chen Y,

Jin HZ,

Yang B,

Li F,

Shi Y,

Gu J,

Guo Q,

Wu L,

Lu T,

Dang L,

Kang X,

Liu X

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

Keywords:

August 2025

Real-world effectiveness of tofacitinib on ulcerative colitis-associated spondyloarthropathy: A multicenter prospective study from the Italian group for the study of inflammatory bowel diseases (IG-IBD)

Ther Adv Gastroenterol 2025;18:1–11 Doi: 10.1177/17562848251367559

Macaluso FS,

Grova M,

Bossa F,

Sorge A,

Festa S,

Onali S,

Orlando A; Italian Group for the study of Inflammatory Bowel Diseases (IG-IBD)

In patients with UC and refractory spondyloarthritis (SpA)—many of whom had previously failed multiple biologic therapies—TOF demonstrated effectiveness, particularly in those with peripheral SpA. Macaluso et al. assessed the effectiveness of TOF in UC-associated SpA. Articular responses were evaluated using rheumatologic scores.

Keywords:

Comparative effectiveness and safety of adalimumab, secukinumab, and upadacitinib in psoriatic arthritis: A prospective cohort study based on PARWCH cohort

J Dermatol 2025 Doi: 10.1111/1346-8138.17906 Epub ahead of print

Wang Y,

Gao J,

Li F,

Li L,

Xiao Y,

Hu H,

Peng X,

Yang M,

Hao D,

Yan W,

Xia D,

Li W

Wang et al. validated the effectiveness and safety of UPA in this real-world study of Chinese PsA patients. UPA demonstrated comparable effectiveness to secukinumab (SEC) in psoriatic lesion improvement while showing comparable joint symptom relief compared with adalimumab (ADA), coupled with a favourable safety profile.